• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    National Vision Holdings, Inc. Reports Second Quarter 2025 Financial Results

    8/6/25 6:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care
    Get the next $EYE alert in real time by email

    Accelerated Initiatives Drive Comparable Store Sales Growth and Improved Profitability Raises Fiscal 2025 Outlook

    Second quarter 2025 highlights compared to second quarter 2024:

    • Net revenue from continuing operations increased 7.7% to $486.4 million
    • Comparable store sales growth of 6.5% and Adjusted Comparable Store Sales Growth of 5.9% represented the 10th consecutive quarter of positive growth
    • Income from continuing operations of $8.7 million, Diluted EPS from continuing operations of $0.11
    • Adjusted Operating Income from continuing operations of $23.8 million, up 69.1%, with Adjusted Operating Margin improving to 4.9% from 3.1%
    • Adjusted Diluted EPS from continuing operations increased to $0.18 from $0.15

    National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision," "we," "our," "us" or the "Company") today reported its financial results for the second quarter ended June 28, 2025.

    "Our strong performance this quarter reflects the continued successful execution of our transformation program and the dedicated efforts of our entire National Vision team," said Alex Wilkes, National Vision's CEO. "The implementation of our lifestyle selling approach, combined with strategic refinements to our assortment and pricing architecture, has supported solid positive comparable sales growth across our brands. We are particularly encouraged by the customer response to our enhanced product offerings and elevated shopping experience at America's Best, which complement our new brand promise that ‘Every Eye Deserves Better.' This upcoming campaign is more than a message, it's a tangible symbol of the modernization of our business while remaining rooted in our mission to deliver affordable, accessible, high-quality eye care and eyewear."

    Mr. Wilkes continued, "Looking ahead, we remain confident in our strategic direction as reflected in our improved outlook for the year. We will continue to build on this momentum by leveraging our modernized brand advertising, personalized marketing, further optimization of our merchandise mix, and disciplined cost management. We have a robust pipeline of initiatives, an experienced leadership team, and a renewed commitment to delivering excellence in eye care, which position us well to deliver sustainable growth and long-term value creation for our shareholders."

    This release includes certain Non-GAAP Financial Measures that are not recognized under generally accepted accounting principles ("GAAP"). Please see "Non-GAAP Financial Measures" and "Reconciliation of Non-GAAP to GAAP Financial Measures" below for more information.

    Results for all periods presented are reported on a continuing operations basis and reflect the results of our former Legacy segment and the substantial majority of AC Lens operations as discontinued operations. Unless otherwise noted, all comparisons are to the prior year period.

    Second Quarter 2025 Summary

    • Net revenue increased 7.7% to $486.4 million, and includes a positive 0.6% impact from the timing of unearned revenue.
    • Comparable store sales growth was 6.5% and Adjusted Comparable Store Sales Growth was 5.9%, both reflecting a higher average ticket and continued strength in the managed care cohort, partially offset by a slight decrease in customer traffic.
    • The Company opened eight new America's Best stores and closed five America's Best stores, ending the quarter with 1,240 stores. Overall, store count grew 2.0%.
    • Costs applicable to revenue increased 3.5% to $200.4 million. As a percentage of net revenue, costs applicable to revenue decreased 170 basis points to 41.2%, primarily driven by the successful execution of pricing and product mix initiatives and the leveraging of optometrist-related costs.
    • Selling, general and administrative expenses (SG&A) increased 6.8% to $247.2 million. As a percentage of net revenue, SG&A decreased 40 basis points to 50.8%, driven by lower expenses and fees, partially offset by higher variable incentive compensation expenses related to revenue and profitability growth. Adjusted SG&A increased 8.2% to $240.0 million and represented 49.3% of net revenue, an increase of 20 basis points. The prior year comparison is impacted by fewer adjustments this year compared to the prior year.
    • Income (loss) from continuing operations increased to $8.7 million, compared to $(1.0) million in the prior-year period. Income (loss) from continuing operations margin improved to 1.8% from (0.2)%.
    • Diluted earnings (loss) per share (EPS) from continuing operations increased to $0.11, compared to $(0.01). Adjusted Diluted EPS increased to $0.18 from $0.15. The net change in margin on unearned revenue benefited both Diluted EPS and Adjusted Diluted EPS by $0.02.
    • Adjusted Operating Income increased 69.1% to $23.8 million. Adjusted Operating Margin improved to 4.9% from 3.1%. The net change in margin on unearned revenue benefited income (loss) from continuing operations, by $1.4 million and Adjusted Operating Income by $1.9 million.

    Year-to-Date 2025 Summary

    • Net revenue increased 6.7% to $996.7 million and includes a negative (0.5)% impact from the timing of unearned revenue.
    • Comparable store sales growth was 5.2% and Adjusted Comparable Store Sales Growth was 5.7%, primarily due to higher average ticket, a slight increase in customer traffic and continued strength in the managed care cohort.
    • The Company opened 17 new America's Best stores, closed nine Fred Meyer stores and closed eight America's Best stores, ending the period with 1,240 stores. Overall, store count grew 2.0%.
    • Costs applicable to revenue increased 4.2% to $405.6 million. As a percentage of net revenue, costs applicable to revenue decreased 90 basis points to 40.7%, mainly due to the successful execution of pricing and product mix initiatives, partially offset by a slight decrease in product margins of contact lenses.
    • SG&A increased 6.6% to $502.7 million. As a percentage of net revenue, SG&A decreased 10 basis points to 50.4% of revenue. Adjusted SG&A increased 6.4% to $481.0 million and represented 48.3% of net revenue, a decrease of 10 basis points.
    • Income from continuing operations increased to $22.9 million compared to $10.7 million. Income from continuing operations margin increased to 2.3% compared to 1.1%.
    • Diluted EPS from continuing operations increased to $0.29 compared to $0.14. Adjusted Diluted EPS increased to $0.52 compared to $0.44. The net change in margin on unearned revenue negatively impacted both Diluted EPS and Adjusted Diluted EPS by $(0.03).
    • Adjusted Operating Income increased 35.7% to $65.1 million. Adjusted Operating Margin increased to 6.5% compared to 5.1% . The net change in margin on unearned revenue negatively impacted income from continuing operations by $(2.8) million and Adjusted Operating Income by $(3.7) million.

    Balance Sheet and Cash Flow Highlights as of June 28, 2025

    • On May 15, 2025, the Company settled the remaining $84.8 million aggregate principal amount of 2.5% unsecured convertible senior notes due May 15, 2025. The settlement was made with $59.8 million from cash on hand and the remaining borrowed under the Company's revolving credit facility.
    • National Vision's cash balance was $48.5 million as of June 28, 2025. The Company has $15.0 million outstanding under its $300.0 million first lien revolving credit facility, exclusive of letters of credit of $6.4 million.
    • Total debt was $272.4 million as of June 28, 2025, consisting of outstanding first lien term loans, revolving loans and finance lease obligations, net of unamortized discounts.

    Fiscal 2025 Outlook

    The Company is raising certain elements of its fiscal 2025 outlook for the 53 weeks ending January 3, 2026, as set forth below. The Company estimates the 53rd week of fiscal 2025 will contribute approximately $35 million to net revenue, and approximately $3 million to Adjusted Operating Income.

     

    Prior Fiscal 2025 Outlook

    (As of May 7, 2025)

    Updated Fiscal 2025 Outlook

    (As of August 6, 2025)

    New Stores

    30-35

    ~32

    Adjusted Comparable Store Sales Growth(1)(2)

    1.5% - 3.5%

    3.0% - 5.0%

    Net Revenue

    $1.919 billion - $1.955 billion

    $1.934 billion - $1.970 billion

    Adjusted Operating Income(2)

    $81 million - $92 million

    $85 million - $95 million

    Adjusted Diluted EPS(2)(3)

    $0.59 - $0.67

    $0.62 - $0.70

    Depreciation and Amortization(4)

    $93 million - $96 million

    $93 million - $96 million

    Interest(5)

    $17 million - $19 million

    $17 million - $19 million

    Tax Rate(6)

    27%

    27%

    Capital Expenditures

    $90 million - $95 million

    $87 million - $90 million

    1

    For the 52 weeks ending December 27, 2025.

    2

    Refer to "Non-GAAP Financial Measures" below for more information.

    3

    Assumes approximately 80 million shares.

    4

    Includes amortization of acquisition intangibles of approximately $0.7 million, which is excluded in the definition of Adjusted Operating Income.

    5

    Before the impact of gains or losses on change in fair value of derivatives and charges related to debt discounts and deferred financing costs.

    6

    Excluding the impact of vesting of restricted stock units and stock option exercises.

    The fiscal 2025 outlook information provided in this release includes Adjusted Operating Income and Adjusted Diluted EPS guidance. The Company is not able to reconcile these forward-looking non-GAAP measures to GAAP without unreasonable efforts because it is not possible to predict with a reasonable degree of certainty the actual impact of certain items and unanticipated events, including taxes and non-recurring items, which would be included in GAAP results.

    The fiscal 2025 outlook is forward-looking, subject to significant business, economic, regulatory and competitive uncertainties and contingencies, many of which are beyond the control of the Company and its management, and based upon assumptions with respect to future decisions, which are subject to change. These uncertainties include, but are not limited to, dynamic market conditions, unexpected disruptions including additional regulatory actions impacting international trade such as tariffs, and other macroeconomic risks and uncertainties. Actual results may vary and those variations may be material. As such, the Company's results may not fall within the ranges contained in its fiscal 2025 outlook. The Company uses these forward-looking measures internally to assess and benchmark its results and strategic plans. See "Forward-Looking Statements" below.

    Announces Investor and Analyst Day

    The Company announced today that it will host an Investor and Analyst Day in New York on November 17, 2025. The presentation and live webcast will be available at www.ir.nationalvision.com. Due to limited capacity, in-person attendance is by invitation only and advance registration is required. Additional details regarding event registration will be provided by Investor Relations in the coming weeks.

    Conference Call Details

    The Company will host a conference call to discuss the second quarter 2025 financial results and fiscal-year 2025 guidance today, August 6, 2025, at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode please refer to the "Investors" section of the Company's website at www.ir.nationalvision.com. A live audio webcast of the conference call will be available on the "Investors" section of the Company's website at www.ir.nationalvision.com, where presentation materials will be posted prior to the conference call. A replay of the audio webcast will also be archived on the "Investors" section of the Company's website.

    About National Vision Holdings, Inc.

    National Vision Holdings, Inc. (NASDAQ:EYE) is one of the largest optical retail companies in the United States with over 1,200 stores in 38 states and Puerto Rico. With a mission of helping people by making quality eye care and eyewear more affordable and accessible, the company operates four retail brands: America's Best Contacts & Eyeglasses, Eyeglass World, and Vista Opticals inside select Fred Meyer stores and on select military bases, and an e-commerce website DiscountContacts.com, offering a variety of products and services for customers' eye care needs. For more information, please visit www.nationalvision.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934. These statements include, but are not limited to, statements contained under "Fiscal 2025 Outlook" as well as other statements related to our current beliefs and expectations regarding the performance of our industry, the Company's strategic direction, market position, prospects including remote medicine and optometrist recruiting and retention initiatives, and future results. You can identify these forward-looking statements by the use of words such as "outlook," "guidance," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "projects," "predicts," "intends," "plans," "estimates," "anticipates" or variations of these words or other comparable words. Caution should be taken not to place undue reliance on any forward-looking statement as such statements speak only as of the date when made. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. Forward-looking statements are not guarantees and are subject to various risks and uncertainties, which may cause actual results to differ materially from those implied in forward-looking statements. Such factors include, but are not limited to, market volatility, an overall decline in the health of the economy, global macroeconomic conditions and other factors that may affect consumer spending or behavior; our ability to successfully implement our transformation initiatives, or anticipate the impact of important strategic initiatives; our ability to recruit and retain vision care professionals for in-store roles or to provide remote care offerings; our ability to compete in the highly competitive optical retail industry; the success of our marketing, advertising and promotional efforts; our ability to maintain, protect, and enhance the value of our owned brands; our ability to open and operate new stores (including as a result of store conversions) in a timely and cost-effective manner or to successfully enter new markets; our ability to increase sales in existing stores and to successfully reinvest in existing stores; our ability to successfully implement our pricing strategies; changes in the cost of inputs, and factors such as wage rate increases, inflation, cost increases, increases in the price of raw materials and energy prices; significant capital requirements to fund our expanding business including updating our Enterprise Resource Planning ("ERP") and Customer Relationship Management ("CRM"), and other technological, systems and capabilities; the potential for our growth strategy to strain our existing resources and cause the performance of our existing stores to suffer; risks associated with leasing substantial amounts of space, including future increases in occupancy costs; our ability to successfully manage the distinct risks faced by our e-commerce and omni-channel business; our ability to retain our existing senior management team or attract qualified new personnel; seasonal fluctuations in our operating results and inventory levels fluctuate; the potential impacts of catastrophic events, including changing climate and weather patterns leading to severe weather and natural disasters; the potential for certain technological advances, greater availability of, or increased consumer preferences for, vision correction alternatives to prescription eyeglasses or contact lenses, or future drug development for the correction of vision-related problems to reduce the demand for our products; our ability to successfully manage our inventory balances and inventory shrinkage; the potential for the loss of, or disruption in the operations of, one or more of our distribution centers or optical laboratories, which would impact our ability to process and fulfill customer orders and deliver our products in a timely manner, or at all, or result in quality issues; the performance of our Host brands and our ability to maintain or extend our operating relationships with our Host partners; impacts resulting from the termination of our partnership with Walmart; our investments in technological innovators in the optical retail industry, including artificial intelligence; sustainability issues, including those related to climate change; our ability to develop, maintain and extend relationships with managed vision care companies, vision insurance providers and other third-party payors; risks associated with vendors from whom our products are sourced and our dependence on a limited number of suppliers; the impact of any significant failure, inadequacy, interruption or security breach affecting our information technology systems, or those of our vendors; our reliance on third-party coverage and reimbursement, including government programs, for an increasing portion of our revenues; our ability to comply with state, local and federal vision care and healthcare laws and regulations, as well as managed vision care laws and regulations; liability stemming from rapidly changing and increasingly stringent laws, regulations, contractual obligations, and industry standards relating to privacy, data security and data protection; product liability, product recall or personal injury issues; our ability to comply with laws, regulations and enforcement activities or changes in statutory, regulatory, accounting and other legal requirements; the outcome of legal proceedings relating to our business operations; the protection and validity of our intellectual property; risks related to our indebtedness; changes in interest rates; restrictions in our credit agreement that limit our flexibility in operating our business; and risks related to owning our common stock. Additional information about these and other factors that could cause National Vision's results to differ materially from those described in the forward-looking statements can be found in filings by National Vision with the Securities and Exchange Commission ("SEC"), including our latest Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, which are accessible on the SEC's website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC.

    Non-GAAP Financial Measures

    To supplement the Company's financial information presented in accordance with GAAP and aid understanding of the Company's business performance, the Company uses certain non-GAAP financial measures, namely "EBITDA," "Adjusted Operating Income," "Adjusted Operating Margin," "Adjusted EBITDA," "Adjusted EBITDA Margin," "Adjusted Diluted EPS," "Adjusted Comparable Stores Sales Growth," "Adjusted SG&A," and "Adjusted SG&A Percent of Net Revenue." We believe EBITDA, Adjusted Operating Income, Adjusted Operating Margin, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Diluted EPS, Adjusted SG&A, and Adjusted SG&A Percent of Net Revenue assist investors and analysts in comparing our operating performance across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. Management believes these non-GAAP financial measures are useful to investors in highlighting trends in our operating performance, while other measures can differ significantly depending on long-term strategic decisions regarding capital structure, the tax jurisdictions in which we operate and capital investments. Management uses these non-GAAP financial measures to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish discretionary annual incentive compensation and to compare our performance against that of other peer companies using similar measures. Management supplements GAAP results with non-GAAP financial measures to provide a more complete understanding of the factors and trends affecting the business than GAAP results alone.

    To supplement the Company's comparable store sales growth presented in accordance with GAAP, the Company provides "Adjusted Comparable Store Sales Growth," which is a non-GAAP financial measure we believe is useful because it provides timely and accurate information relating to the two core metrics of retail sales: number of transactions and value of transactions. Management uses Adjusted Comparable Store Sales Growth as the basis for key operating decisions, such as allocation of advertising to particular markets and implementation of special marketing programs. Accordingly, we believe that Adjusted Comparable Store Sales Growth provides timely and accurate information relating to the operational health and overall performance of each brand. We also believe that, for the same reasons, investors find our calculation of Adjusted Comparable Store Sales Growth to be meaningful.

    EBITDA: We define EBITDA from continuing operations as net income (loss), minus income (loss) from discontinued operations, net of tax, plus interest expense (income), net, income tax provision (benefit), and depreciation and amortization.

    Adjusted Operating Income: We define Adjusted Operating Income from continuing operations as net income (loss), minus income (loss) from discontinued operations, net of tax, plus interest expense (income), net and income tax provision (benefit), further adjusted to exclude stock-based compensation expense, (gain) loss on extinguishment of debt, asset impairment, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expenses, amortization of acquisition intangibles, Enterprise Resource Planning ("ERP") and Customer Relationship Management ("CRM") implementation expenses, shareholder activism costs, severance and employee-related costs associated with organizational restructuring and certain other expenses.

    Adjusted Operating Margin: We define Adjusted Operating Margin from continuing operations as Adjusted Operating Income from continuing operations as a percentage of total net revenue.

    Adjusted EBITDA: We define Adjusted EBITDA from continuing operations as net income (loss), minus income (loss) from discontinued operations, net of tax, plus interest expense (income), net, income tax provision and depreciation and amortization, further adjusted to exclude stock-based compensation expense, (gain) loss on extinguishment of debt, asset impairment, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expenses, ERP and CRM implementation expenses, shareholder activism, severance and employee-related costs associated with restructuring and certain other expenses.

    Adjusted EBITDA Margin: We define Adjusted EBITDA Margin from continuing operations as Adjusted EBITDA from continuing operations as a percentage of total net revenue.

    Adjusted Diluted EPS: We define Adjusted Diluted EPS from continuing operations as diluted earnings (loss) per share, minus diluted earnings (loss) per share from discontinued operations, adjusted for the per share impact of stock-based compensation expense, (gain) loss on extinguishment of debt, asset impairment, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expenses, amortization of acquisition intangibles, amortization of debt discounts and deferred financing costs of our term loan borrowings, amortization of the conversion feature and deferred financing costs related to our 2025 Notes when not required under U.S. GAAP to be added back for diluted earnings (loss) per share, derivative fair value adjustments, ERP and CRM implementation expenses, shareholder activism, severance and employee-related costs associated with restructuring and certain other expenses, and related tax effects.

    Adjusted SG&A: We define Adjusted SG&A from continuing operations as SG&A from continuing operations adjusted to exclude stock-based compensation expense, litigation settlement, secondary offering expenses, management realignment expenses, long-term incentive plan expense, ERP and CRM implementation expenses, shareholder activism, severance and employee-related costs associated with restructuring and certain other expenses.

    Adjusted SG&A Percent of Net Revenue: We define Adjusted SG&A Percent of Net Revenue from continuing operations as Adjusted SG&A from continuing operations as a percentage of total net revenue.

    Adjusted Comparable Store Sales Growth: We measure Adjusted Comparable Store Sales Growth as the increase or decrease in sales recorded by the comparable store base in any reporting period, compared to sales recorded by the comparable store base in the prior reporting period, which we calculate as follows: (i) sales are recorded on a cash basis (i.e. when the order is placed and paid for or submitted to a managed care payor, compared to when the order is delivered), utilizing cash basis point of sale information from stores; (ii) stores are added to the calculation during the 13th full fiscal month following the store's opening; (iii) closed stores are removed from the calculation for time periods that are not comparable; (iv) sales from partial months of operation are excluded when stores do not open or close on the first day of the month; and (v) when applicable, we adjust for the effect of the 53rd week. Quarterly, year-to-date and annual adjusted comparable store sales are aggregated using only sales from all whole months of operation included in both the current reporting period and the prior reporting period. When a partial month is excluded from the calculation, the corresponding month in the subsequent period is also excluded from the calculation. There may be variations in the way in which some of our competitors and other retailers calculate comparable store sales. As a result, our adjusted comparable store sales may not be comparable to similar data made available by other retailers.

    EBITDA, Adjusted Operating Income, Adjusted Operating Margin, Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Diluted EPS, Adjusted SG&A, Adjusted SG&A Percent of Net Revenue and Adjusted Comparable Store Sales Growth are not recognized terms under U.S. GAAP and should not be considered as an alternative to net income or the ratio of net income to net revenue as a measure of financial performance, SG&A, the ratio of SG&A to net revenue as a measure of financial performance, cash flows provided by operating activities as a measure of liquidity, comparable store sales growth as a measure of operating performance, or any other performance measure derived in accordance with U.S. GAAP. Additionally, these measures are not intended to be a measure of free cash flow available for management's discretionary use as they do not consider certain cash requirements such as interest payments, tax payments and debt service requirements. The presentations of these measures have limitations as analytical tools and should not be considered in isolation, or as a substitute for analysis of our results as reported under U.S. GAAP. Because not all companies use identical calculations, the presentations of these measures may not be comparable to other similarly titled measures of other companies and can differ significantly from company to company.

    Please see "Reconciliation of Non-GAAP to GAAP Financial Measures" below for reconciliations of non-GAAP financial measures used in this release to their most directly comparable GAAP financial measures.

    National Vision Holdings, Inc. and Subsidiaries

    Condensed Consolidated Balance Sheets (Unaudited)

     

    In Thousands, Except Par Value

    As of

    June 28, 2025

     

    As of

    December 28, 2024

    ASSETS

     

     

     

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    48,471

     

     

    $

    73,948

     

    Accounts receivable, net

     

    45,958

     

     

     

    49,938

     

    Inventories, net

     

    89,648

     

     

     

    93,918

     

    Prepaid expenses and other current assets

     

    33,624

     

     

     

    32,024

     

    Total current assets

     

    217,701

     

     

     

    249,828

     

     

     

     

     

    Noncurrent assets:

     

     

     

    Property and equipment, net

     

    350,803

     

     

     

    362,175

     

    Goodwill

     

    698,305

     

     

     

    698,305

     

    Trademarks and trade names

     

    240,547

     

     

     

    240,547

     

    Other intangible assets, net

     

    7,905

     

     

     

    8,269

     

    Right of use assets

     

    391,632

     

     

     

    408,589

     

    Other assets

     

    61,459

     

     

     

    40,058

     

    Total noncurrent assets

     

    1,750,651

     

     

     

    1,757,943

     

    Total assets

    $

    1,968,352

     

     

    $

    2,007,771

     

     

     

     

     

    LIABILITIES AND STOCKHOLDERS' EQUITY

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    65,099

     

     

    $

    53,643

     

    Other payables and accrued expenses

     

    126,730

     

     

     

    109,036

     

    Unearned revenue

     

    42,689

     

     

     

    42,002

     

    Deferred revenue

     

    64,733

     

     

     

    62,507

     

    Current maturities of long-term debt and finance lease obligations

     

    16,782

     

     

     

    101,392

     

    Current operating lease obligations

     

    102,213

     

     

     

    99,694

     

    Total current liabilities

     

    418,246

     

     

     

    468,274

     

     

     

     

     

    Noncurrent liabilities:

     

     

     

    Long-term debt and finance lease obligations, less current portion and debt discount

     

    255,620

     

     

     

    248,610

     

    Noncurrent operating lease obligations

     

    344,727

     

     

     

    366,335

     

    Deferred revenue

     

    22,778

     

     

     

    22,082

     

    Other liabilities

     

    8,291

     

     

     

    8,228

     

    Deferred income taxes, net

     

    68,109

     

     

     

    77,909

     

    Total non-current liabilities

     

    699,525

     

     

     

    723,164

     

    Commitments and contingencies

     

     

     

    Stockholders' equity:

     

     

     

    Common stock, $0.01 par value; 200,000 shares authorized; 85,977 and 85,444 shares issued as of June 28, 2025 and December 28, 2024, respectively; 79,175 and 78,775 shares outstanding as of June 28, 2025 and December 28, 2024, respectively

     

    859

     

     

     

    854

     

    Additional paid-in capital

     

    820,059

     

     

     

    807,048

     

    Retained earnings

     

    249,028

     

     

     

    226,117

     

    Treasury stock, at cost; 6,802 and 6,669 shares as of June 28, 2025 and December 28, 2024, respectively

     

    (219,365

    )

     

     

    (217,686

    )

    Total stockholders' equity

     

    850,581

     

     

     

    816,333

     

    Total liabilities and stockholders' equity

    $

    1,968,352

     

     

    $

    2,007,771

     

    National Vision Holdings, Inc. and Subsidiaries

    Condensed Consolidated Statements of Operations and Comprehensive Income (Unaudited)

     

     

    Three Months Ended

     

    Six Months Ended

    In thousands, except per share amounts

    June 28, 2025

     

    June 29, 2024

     

    June 28, 2025

     

    June 29, 2024

    Revenue:

     

     

     

     

     

     

     

    Net product sales

    $

    394,589

     

     

    $

    361,967

     

     

    $

    807,354

     

     

    $

    750,050

     

    Net sales of services and plans

     

    91,834

     

     

     

    89,766

     

     

     

    189,393

     

     

     

    184,477

     

    Total net revenue

     

    486,423

     

     

     

    451,733

     

     

     

    996,747

     

     

     

    934,527

     

    Costs applicable to revenue (exclusive of depreciation and amortization):

     

     

     

     

     

     

     

    Products

     

    114,686

     

     

     

    111,213

     

     

     

    231,600

     

     

     

    224,417

     

    Services and plans

     

    85,685

     

     

     

    82,367

     

     

     

    173,961

     

     

     

    164,709

     

    Total costs applicable to revenue

     

    200,371

     

     

     

    193,580

     

     

     

    405,561

     

     

     

    389,126

     

    Operating expenses:

     

     

     

     

     

     

     

    Selling, general and administrative expenses

     

    247,167

     

     

     

    231,353

     

     

     

    502,699

     

     

     

    471,481

     

    Depreciation and amortization

     

    22,536

     

     

     

    22,692

     

     

     

    45,499

     

     

     

    45,913

     

    Asset impairment

     

    —

     

     

     

    3,519

     

     

     

    502

     

     

     

    3,975

     

    Other expense (income), net

     

    (100

    )

     

     

    (2

    )

     

     

    (100

    )

     

     

    (1

    )

    Total operating expenses

     

    269,603

     

     

     

    257,562

     

     

     

    548,600

     

     

     

    521,368

     

    Income from operations

     

    16,449

     

     

     

    591

     

     

     

    42,586

     

     

     

    24,033

     

    Interest expense, net

     

    4,210

     

     

     

    3,196

     

     

     

    8,782

     

     

     

    7,452

     

    Earnings (loss) from continuing operations before income taxes

     

    12,239

     

     

     

    (2,605

    )

     

     

    33,804

     

     

     

    16,581

     

    Income tax provision (benefit)

     

    3,514

     

     

     

    (1,564

    )

     

     

    10,893

     

     

     

    5,869

     

    Income (loss) from continuing operations

     

    8,725

     

     

     

    (1,041

    )

     

     

    22,911

     

     

     

    10,712

     

    Loss from discontinued operations, net of tax

     

    —

     

     

     

    (2,084

    )

     

     

    —

     

     

     

    (2,152

    )

    Net income (loss)

    $

    8,725

     

     

    $

    (3,125

    )

     

    $

    22,911

     

     

    $

    8,560

     

     

     

     

     

     

     

     

     

    Basic earnings (loss) per share:

     

     

     

     

     

     

     

    Continuing operations

    $

    0.11

     

     

    $

    (0.01

    )

     

    $

    0.29

     

     

    $

    0.14

     

    Discontinued operations

    $

    —

     

     

    $

    (0.03

    )

     

    $

    —

     

     

    $

    (0.03

    )

    Total

    $

    0.11

     

     

    $

    (0.04

    )

     

    $

    0.29

     

     

    $

    0.11

     

    Diluted earnings (loss) per share:

     

     

     

     

     

     

     

    Continuing operations

    $

    0.11

     

     

    $

    (0.01

    )

     

    $

    0.29

     

     

    $

    0.14

     

    Discontinued operations

    $

    —

     

     

    $

    (0.03

    )

     

    $

    —

     

     

    $

    (0.03

    )

    Total

    $

    0.11

     

     

    $

    (0.04

    )

     

    $

    0.29

     

     

    $

    0.11

     

     

     

     

     

     

     

     

     

    Weighted average shares outstanding:

     

     

     

     

     

     

     

    Basic

     

    79,079

     

     

     

    78,575

     

     

     

    78,968

     

     

     

    78,480

     

    Diluted

     

    80,057

     

     

     

    78,575

     

     

     

    79,658

     

     

     

    78,774

     

     

     

     

     

     

     

     

     

    Comprehensive income:

     

     

     

     

     

     

     

    Net income (loss)

    $

    8,725

     

     

    $

    (3,125

    )

     

    $

    22,911

     

     

    $

    8,560

     

    Unrealized gain on hedge instruments

     

    —

     

     

     

    229

     

     

     

    —

     

     

     

    483

     

    Tax provision of unrealized gain on hedge instruments

     

    —

     

     

     

    64

     

     

     

    —

     

     

     

    128

     

    Comprehensive income (loss)

    $

    8,725

     

     

    $

    (2,960

    )

     

    $

    22,911

     

     

    $

    8,915

     

    National Vision Holdings, Inc. and Subsidiaries

    Condensed Consolidated Statements of Cash Flows (Unaudited)

     

     

    Six Months Ended

    In Thousands

    June 28, 2025

     

    June 29, 2024

    Cash flows from operating activities:

     

     

     

    Net income

    $

    22,911

     

     

    $

    8,560

     

    Adjustments to reconcile net income to net cash provided by operating activities:

     

     

     

    Depreciation and amortization

     

    45,499

     

     

     

    47,244

     

    Amortization of debt discount and deferred financing costs

     

    674

     

     

     

    1,261

     

    Amortization of cloud computing implementation costs

     

    4,636

     

     

     

    2,330

     

    Asset impairment

     

    502

     

     

     

    3,975

     

    Deferred income tax expense (benefit)

     

    (9,800

    )

     

     

    (5,425

    )

    Stock-based compensation expense

     

    12,335

     

     

     

    7,246

     

    (Gains) on change in fair value of derivatives

     

    —

     

     

     

    (66

    )

    Inventory adjustments

     

    1,801

     

     

     

    2,951

     

    Other

     

    (149

    )

     

     

    1,218

     

    Changes in operating assets and liabilities:

     

     

     

    Accounts receivable

     

    3,629

     

     

     

    24,351

     

    Inventories

     

    2,469

     

     

     

    26,000

     

    Operating lease right of use assets and lease liabilities

     

    (1,117

    )

     

     

    (1,722

    )

    Other assets

     

    (26,815

    )

     

     

    1,248

     

    Accounts payable

     

    11,456

     

     

     

    (17,587

    )

    Deferred and unearned revenue

     

    3,609

     

     

     

    (6,721

    )

    Other liabilities

     

    14,860

     

     

     

    (19,415

    )

    Net cash provided by operating activities

     

    86,500

     

     

     

    75,448

     

    Cash flows from investing activities:

     

     

     

    Purchase of property and equipment

     

    (32,075

    )

     

     

    (39,620

    )

    Other

     

    (849

    )

     

     

    1,577

     

    Net cash used for investing activities

     

    (32,924

    )

     

     

    (38,043

    )

    Cash flows from financing activities:

     

     

     

    Repayments on long-term debt

     

    (91,399

    )

     

     

    (3,750

    )

    Borrowings on long-term debt

     

    15,000

     

     

     

    —

     

    Proceeds from issuance of common stock

     

    736

     

     

     

    670

     

    Purchase of treasury stock

     

    (1,679

    )

     

     

    (2,775

    )

    Payments on finance lease obligations

     

    (1,483

    )

     

     

    (1,585

    )

    Net cash used for financing activities

     

    (78,825

    )

     

     

    (7,440

    )

    Net change in cash, cash equivalents and restricted cash

     

    (25,249

    )

     

     

    29,965

     

    Cash, cash equivalents and restricted cash, beginning of year

     

    75,237

     

     

     

    151,027

     

    Cash, cash equivalents and restricted cash, end of period (i)

    $

    49,988

     

     

    $

    180,992

     

     

    (i) Cash balance includes restricted cash of $1.5 million and $1.5 million for the six months ended June 28, 2025 and June 29, 2024, respectively, that are not reflected in cash and cash equivalents shown on the Condensed Consolidated Balance Sheets.

    National Vision Holdings, Inc. and Subsidiaries

    Reconciliation of Non-GAAP to GAAP Financial Measures (Unaudited) 

     

    Reconciliation of Adjusted Operating Income from Continuing Operations to Net Income (Loss)

     

    Three Months Ended

     

    Six Months Ended

    In thousands

    June 28, 2025

     

    June 29, 2024

     

    June 28, 2025

     

    June 29, 2024

    Net income (loss)

    $

    8,725

     

     

    $

    (3,125

    )

     

    $

    22,911

     

     

    $

    8,560

     

    Income (loss) from discontinued operations, net of tax

     

    —

     

     

     

    (2,084

    )

     

     

    —

     

     

     

    (2,152

    )

    Income (loss) from continuing operations

     

    8,725

     

     

     

    (1,041

    )

     

     

    22,911

     

     

     

    10,712

     

    Interest expense, net

     

    4,210

     

     

     

    3,196

     

     

     

    8,782

     

     

     

    7,452

     

    Income tax provision (benefit)

     

    3,514

     

     

     

    (1,564

    )

     

     

    10,893

     

     

     

    5,869

     

    Stock-based compensation expense (a)

     

    5,306

     

     

     

    4,750

     

     

     

    12,335

     

     

     

    7,164

     

    Asset impairment (b)

     

    —

     

     

     

    3,519

     

     

     

    502

     

     

     

    3,975

     

    Litigation settlement (c)

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    4,450

     

    Amortization of acquisition intangibles (d)

     

    169

     

     

     

    382

     

     

     

    338

     

     

     

    763

     

    ERP and CRM implementation expenses (g)

     

    1,846

     

     

     

    2,141

     

     

     

    4,161

     

     

     

    2,657

     

    Other (h)

     

    31

     

     

     

    2,690

     

     

     

    5,154

     

     

     

    4,925

     

    Adjusted Operating Income from continuing operations

    $

    23,801

     

     

    $

    14,073

     

     

    $

    65,076

     

     

    $

    47,967

     

     

     

     

     

     

     

     

     

    Income (loss) from continuing operations margin

     

    1.8

    %

     

     

    (0.2

    )%

     

     

    2.3

    %

     

     

    1.1

    %

    Adjusted Operating Margin from continuing operations

     

    4.9

    %

     

     

    3.1

    %

     

     

    6.5

    %

     

     

    5.1

    %

     

     

     

     

     

     

     

     

    Note: Percentages reflect line item as a percentage of total net revenue, adjusted for rounding.

    Reconciliation of EBITDA from Continuing Operations and Adjusted EBITDA from Continuing Operations to Net Income (Loss)

     

    Three Months Ended

     

    Six Months Ended

    In thousands

    June 28, 2025

     

    June 29, 2024

     

    June 28, 2025

     

    June 29, 2024

    Net income (loss)

    $

    8,725

     

     

    $

    (3,125

    )

     

    $

    22,911

     

     

    $

    8,560

     

    Income (loss) from discontinued operations, net of tax

     

    —

     

     

     

    (2,084

    )

     

     

    —

     

     

     

    (2,152

    )

    Income (loss) from continuing operations

     

    8,725

     

     

     

    (1,041

    )

     

     

    22,911

     

     

     

    10,712

     

    Interest expense, net

     

    4,210

     

     

     

    3,196

     

     

     

    8,782

     

     

     

    7,452

     

    Income tax provision (benefit)

     

    3,514

     

     

     

    (1,564

    )

     

     

    10,893

     

     

     

    5,869

     

    Depreciation and amortization

     

    22,536

     

     

     

    22,692

     

     

     

    45,499

     

     

     

    45,913

     

    EBITDA from continuing operations

     

    38,985

     

     

     

    23,283

     

     

     

    88,085

     

     

     

    69,946

     

     

     

     

     

     

     

     

     

    Stock-based compensation expense (a)

     

    5,306

     

     

     

    4,750

     

     

     

    12,335

     

     

     

    7,164

     

    Asset impairment (b)

     

    —

     

     

     

    3,519

     

     

     

    502

     

     

     

    3,975

     

    Litigation settlement (c)

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    4,450

     

    ERP and CRM implementation expenses (g)

     

    1,846

     

     

     

    2,141

     

     

     

    4,161

     

     

     

    2,657

     

    Other (h)

     

    31

     

     

     

    2,690

     

     

     

    5,154

     

     

     

    4,925

     

    Adjusted EBITDA from continuing operations

    $

    46,168

     

     

    $

    36,383

     

     

    $

    110,237

     

     

    $

    93,117

     

     

     

     

     

     

     

     

     

    Income (loss) from continuing operations margin

     

    1.8

    %

     

     

    (0.2

    )%

     

     

    2.3

    %

     

     

    1.1

    %

    Adjusted EBITDA Margin from continuing operations

     

    9.5

    %

     

     

    8.1

    %

     

     

    11.1

    %

     

     

    10.0

    %

     

     

     

     

     

     

     

     

    Note: Percentages reflect line item as a percentage of total net revenue, adjusted for rounding.

    Reconciliation of Adjusted Diluted EPS from Continuing Operations to Diluted EPS

     

    Three Months Ended

     

    Six Months Ended

    Shares in thousands, except per share amounts

    June 28, 2025

     

    June 29, 2024

     

    June 28, 2025

     

    June 29, 2024

    Diluted EPS

    $

    0.11

     

     

    $

    (0.04

    )

     

    $

    0.29

     

     

    $

    0.11

     

    Diluted EPS from discontinued operations

     

    —

     

     

     

    (0.03

    )

     

     

    —

     

     

     

    (0.03

    )

    Diluted EPS from continuing operations

    $

    0.11

     

     

    $

    (0.01

    )

     

    $

    0.29

     

     

    $

    0.14

     

    Stock-based compensation expense (a)

     

    0.07

     

     

     

    0.06

     

     

     

    0.15

     

     

     

    0.09

     

    Asset impairment (b)

     

    —

     

     

     

    0.04

     

     

     

    0.01

     

     

     

    0.05

     

    Litigation settlement (c)

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    0.06

     

    Amortization of acquisition intangibles (d)

     

    0.00

     

     

     

    0.00

     

     

     

    0.00

     

     

     

    0.01

     

    Amortization of debt discount and deferred financing costs (e)

     

    0.00

     

     

     

    0.01

     

     

     

    0.01

     

     

     

    0.02

     

    Derivatives fair value adjustments (f)

     

    —

     

     

     

    0.04

     

     

     

    —

     

     

     

    0.07

     

    ERP and CRM implementation expenses (g)

     

    0.02

     

     

     

    0.03

     

     

     

    0.05

     

     

     

    0.03

     

    Other (h)

     

    0.00

     

     

     

    0.03

     

     

     

    0.07

     

     

     

    0.06

     

    Tax effects (i)

     

    (0.02

    )

     

     

    (0.05

    )

     

     

    (0.06

    )

     

     

    (0.09

    )

    Adjusted Diluted EPS from continuing operations

    $

    0.18

     

     

    $

    0.15

     

     

    $

    0.52

     

     

    $

    0.44

     

     

     

     

     

     

     

     

     

    Weighted average diluted shares outstanding

     

    80,057

     

     

     

    78,575

     

     

     

    79,658

     

     

     

    78,774

     

     

     

     

     

     

     

     

     

    Reconciliation of Adjusted SG&A from Continuing Operations to SG&A from Continuing Operations

     

    Three Months Ended

     

    Six Months Ended

    In thousands

    June 28, 2025

     

    June 29, 2024

     

    June 28, 2025

     

    June 29, 2024

    SG&A from continuing operations

    $

    247,167

     

     

    $

    231,353

     

     

    $

    502,699

     

     

    $

    471,481

     

    Stock-based compensation expense (a)

     

    5,306

     

     

     

    4,750

     

     

     

    12,335

     

     

     

    7,164

     

    Litigation settlement (c)

     

    —

     

     

     

    —

     

     

     

    —

     

     

     

    4,450

     

    ERP and CRM implementation expenses (g)

     

    1,846

     

     

     

    2,141

     

     

     

    4,161

     

     

     

    2,657

     

    Other (h)

     

    31

     

     

     

    2,690

     

     

     

    5,154

     

     

     

    4,925

     

    Adjusted SG&A from continuing operations

    $

    239,984

     

     

    $

    221,772

     

     

    $

    481,049

     

     

    $

    452,285

     

     

     

     

     

     

     

     

     

    SG&A from continuing operations Percent of Net Revenue

     

    50.8

    %

     

     

    51.2

    %

     

     

    50.4

    %

     

     

    50.5

    %

    Adjusted SG&A from continuing operations Percent of Net Revenue

     

    49.3

    %

     

     

    49.1

    %

     

     

    48.3

    %

     

     

    48.4

    %

    Note: Percentages reflect line item as a percentage of total net revenue.

    (a)

    Non-cash charges related to stock-based compensation programs, which vary from period to period depending on the timing of awards and performance vesting conditions.

    (b)

    Reflects write-off related to non-cash impairment charges of long-lived assets, primarily impairment of property, equipment and lease-related assets on closed or underperforming stores.

    (c)

    Expenses associated with settlement of certain litigation.

    (d)

    Amortization of the increase in carrying values of finite-lived intangible assets resulting from the application of purchase accounting following the acquisition of the Company by affiliates of KKR & Co. Inc.

    (e)

    Amortization of deferred financing costs and other non-cash charges related to our debt. We adjust for amortization of deferred financing costs related to the 2025 Notes only when adjustment for these costs is not required in the calculation of diluted earnings per share under U.S. GAAP.

    (f)

    The adjustments for the derivative fair value (gains) and losses have the effect of adjusting the (gain) or loss for changes in the fair value of derivative instruments and amortization of AOCL for derivatives not designated as accounting hedges. This results in reflecting derivative (gains) and losses within Adjusted Diluted EPS during the period the derivative is settled.

    (g)

    Costs related to the Company's ERP and CRM implementations.

    (h)

    Other adjustments include amounts that management believes are not representative of our operating performance (amounts in brackets represent reductions in Adjusted Operating Income, Adjusted Diluted EPS, Adjusted EBITDA and Adjusted SG&A), which are primarily related to shareholder activism costs of $2.1 million and severance and employee-related costs associated with organizational restructuring of $2.1 million for the six months ended June 28, 2025, costs associated with the digitization of paper-based records of $2.3 million and $4.1 million for the three and six months ended June 29, 2024, respectively, and other expenses and adjustments.

    (i)

    Represents the income tax effect of the total adjustments at our combined statutory federal and state income tax rates, including tax expense (benefit) from stock-based compensation.

    Reconciliation of Adjusted Comparable Store Sales Growth from Continuing Operations to Total Comparable Store Sales Growth from Continuing Operations

     

    Comparable store sales growth from continuing operations (a)

     

    Three Months

    Ended June

    28, 2025

     

    Three Months

    Ended June

    29, 2024

     

    Six Months

    Ended June

    28, 2025

     

    Six Months

    Ended June

    29, 2024

     

    2025 Outlook (b)

    Owned & Host segment

     

     

     

     

     

     

     

     

     

    America's Best

    6.3 %

     

    2.9 %

     

    6.1 %

     

    2.0 %

     

     

    Eyeglass World

    2.8 %

     

    (0.5) %

     

    2.9 %

     

    (2.9) %

     

     

    Military

    4.4 %

     

    (0.1) %

     

    3.0 %

     

    (0.8) %

     

     

    Fred Meyer

    6.9 %

     

    (2.7) %

     

    4.1 %

     

    (4.3) %

     

     

     

     

     

     

     

     

     

     

     

     

    Total comparable store sales growth from continuing operations

    6.5 %

     

    2.2 %

     

    5.2 %

     

    1.8 %

     

    3.5% - 5.5%

    Adjustments for effects of: (b)

     

     

     

     

     

     

     

     

     

    Unearned & deferred revenue

    (0.6) %

     

    0.2 %

     

    0.5 %

     

    (0.5) %

     

     

    Adjusted Comparable Store Sales Growth from continuing operations

    5.9 %

     

    2.4 %

     

    5.7 %

     

    1.3 %

     

    3.0% - 5.0%

    (a) Total comparable store sales from continuing operations is calculated based on consolidated net revenue from continuing operations excluding the impact of (i) other segments revenue, (ii) sales from stores opened less than 13 months, (iii) stores closed in the periods presented, (iv) sales from partial months of operation when stores do not open or close on the first day of the month and (v) if applicable, the impact of a 53rd week in a fiscal year. Brand-level comparable store sales growth is calculated based on cash basis revenues consistent with what the CODM reviews, and consistent with reportable segment revenues presented in Note 16. "Segment Reporting" in our Annual Report on Form 10-K for the period ended December 28, 2024.
    (b) Adjusted Comparable Store Sales Growth from continuing operations includes the effect of deferred and unearned revenue as if such revenues were earned at the point of sale, resulting in the changes from total comparable store sales growth from continuing operations based on consolidated net revenue from continuing operations; with respect to the Company's 2025 Outlook, Adjusted Comparable Store Sales Growth includes an estimated 0.5% decrease for the effect of deferred and unearned revenue as if such revenues were earned at the point of sale.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250806216443/en/

    Investor contact:

    [email protected]



    National Vision Holdings, Inc.

    Tamara Gonzalez



    ICR, Inc.

    Caitlin Churchill



    Media contact:

    [email protected]

    Get the next $EYE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EYE

    DatePrice TargetRatingAnalyst
    7/30/2025$36.00Buy
    Roth Capital
    7/8/2025$30.00Equal Weight → Overweight
    Barclays
    5/9/2025$21.00Neutral → Buy
    Citigroup
    5/7/2025Underperform → Buy
    BofA Securities
    10/17/2023$25.00 → $16.00Buy → Neutral
    Goldman
    7/27/2023$28.00 → $22.00Buy → Neutral
    Citigroup
    7/27/2023$30.00 → $21.00Overweight → Equal Weight
    Wells Fargo
    5/2/2023Overweight → Equal Weight
    Barclays
    More analyst ratings

    $EYE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Peeler D Randolph bought $264,200 worth of shares (25,000 units at $10.57) (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    8/14/24 4:27:52 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Director Hepner Virginia A bought $10,365 worth of shares (1,000 units at $10.37), increasing direct ownership by 3% to 36,635 units (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    8/14/24 4:26:51 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Fahs L Reade bought $299,200 worth of shares (20,000 units at $14.96), increasing direct ownership by 3% to 633,097 units (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    5/14/24 8:01:46 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    National Vision Holdings, Inc. Reports Second Quarter 2025 Financial Results

    Accelerated Initiatives Drive Comparable Store Sales Growth and Improved Profitability Raises Fiscal 2025 Outlook Second quarter 2025 highlights compared to second quarter 2024: Net revenue from continuing operations increased 7.7% to $486.4 million Comparable store sales growth of 6.5% and Adjusted Comparable Store Sales Growth of 5.9% represented the 10th consecutive quarter of positive growth Income from continuing operations of $8.7 million, Diluted EPS from continuing operations of $0.11 Adjusted Operating Income from continuing operations of $23.8 million, up 69.1%, with Adjusted Operating Margin improving to 4.9% from 3.1% Adjusted Diluted EPS from continuing operati

    8/6/25 6:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision, Inc. Unveils Bold New Brand Identity as Part of Strategic Transformation

    Brand refresh underscores National Vision's continued business evolution and unwavering commitment to accessible, high-quality eye care and eyewear DULUTH, Ga., Aug. 5, 2025 /PRNewswire/ -- National Vision Holdings, Inc. (NASDAQ:EYE), one of the largest optical retail companies in the United States, unveiled its new corporate brand identity, a major milestone in National Vision's transformation journey. The refreshed branding strengthens National Vision's position as a modern, agile and purpose-driven organization committed to helping people see their best to live their best. Experience the full interactive Multichannel News Release here: https://www.multivu.com/national-vision-holdings/934

    8/5/25 8:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Releases Annual Sustainability Report Highlighting 2024 Progress

    National Vision, Inc., one of the largest optical retail companies in the U.S., released its 2024 Sustainability Report, "A World Worth Seeing." The report focuses on the company's performance across its Social, Employees, Environment and Governance (SEE+G) framework, and reflects continued progress against the environmental, social and governance (ESG) issues that matter most to the company's business and stakeholders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250730016841/en/National Vision released its 2024 Sustainability Report, "A World Worth Seeing." "This past year, our refreshed leadership team made significant stri

    7/30/25 8:21:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by National Vision Holdings Inc.

    SCHEDULE 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

    8/13/25 4:00:04 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    SEC Form 10-Q filed by National Vision Holdings Inc.

    10-Q - National Vision Holdings, Inc. (0001710155) (Filer)

    8/7/25 8:33:06 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - National Vision Holdings, Inc. (0001710155) (Filer)

    8/6/25 6:07:10 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on National Vision with a new price target

    Roth Capital initiated coverage of National Vision with a rating of Buy and set a new price target of $36.00

    7/30/25 7:33:08 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision upgraded by Barclays with a new price target

    Barclays upgraded National Vision from Equal Weight to Overweight and set a new price target of $30.00

    7/8/25 8:23:14 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision upgraded by Citigroup with a new price target

    Citigroup upgraded National Vision from Neutral to Buy and set a new price target of $21.00

    5/9/25 8:39:42 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Wilkes Alexander

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    8/4/25 4:32:18 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    President, America's Best Banner Mark converted options into 11,728 shares and covered exercise/tax liability with 3,462 shares (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    7/9/25 4:21:56 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Director Zulla Caitlin was granted 10,870 units of Restricted Stock Units, increasing direct ownership by 99% to 21,880 units (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    6/23/25 4:40:50 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Financials

    Live finance-specific insights

    View All

    National Vision Holdings, Inc. Reports Second Quarter 2025 Financial Results

    Accelerated Initiatives Drive Comparable Store Sales Growth and Improved Profitability Raises Fiscal 2025 Outlook Second quarter 2025 highlights compared to second quarter 2024: Net revenue from continuing operations increased 7.7% to $486.4 million Comparable store sales growth of 6.5% and Adjusted Comparable Store Sales Growth of 5.9% represented the 10th consecutive quarter of positive growth Income from continuing operations of $8.7 million, Diluted EPS from continuing operations of $0.11 Adjusted Operating Income from continuing operations of $23.8 million, up 69.1%, with Adjusted Operating Margin improving to 4.9% from 3.1% Adjusted Diluted EPS from continuing operati

    8/6/25 6:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Holdings, Inc. Announces Second Quarter 2025 Earnings Release and Conference Call

    National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") will report its second quarter 2025 financial results before the market opens on Wednesday, August 6, 2025, and will host a conference call at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode, please refer to the "Investors" section of the Company's website at https://ir.nationalvision.com/. A live audio webcast of the conference call, together with related materials, will be available online in the "Investors" section of the Company's website. A replay of the audio webcast will be available shortly after the broadcast. About National Vision Holdings,

    7/23/25 8:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Holdings, Inc. Reports First Quarter 2025 Financial Results

    Successful Execution of New Transformation Initiatives and Cost Reduction Actions Delivered Strong First Quarter First quarter 2025 highlights compared to Q1 2024: Net revenue from continuing operations of $510.3 million, an increase of 5.7% Comparable store sales growth of 4.1% and Adjusted Comparable Store Sales Growth of 5.5% represented the 9th consecutive quarter of positive growth Income from continuing operations of $14.2 million, Diluted EPS from continuing operations of $0.18 Adjusted Operating Income from continuing operations of $41.3 million Adjusted Diluted EPS from continuing operations of $0.34 Raises fiscal 2025 outlook National Vision Holdings, Inc. (NASDAQ:E

    5/7/25 6:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Leadership Updates

    Live Leadership Updates

    View All

    National Vision, Inc. Unveils Bold New Brand Identity as Part of Strategic Transformation

    Brand refresh underscores National Vision's continued business evolution and unwavering commitment to accessible, high-quality eye care and eyewear DULUTH, Ga., Aug. 5, 2025 /PRNewswire/ -- National Vision Holdings, Inc. (NASDAQ:EYE), one of the largest optical retail companies in the United States, unveiled its new corporate brand identity, a major milestone in National Vision's transformation journey. The refreshed branding strengthens National Vision's position as a modern, agile and purpose-driven organization committed to helping people see their best to live their best. Experience the full interactive Multichannel News Release here: https://www.multivu.com/national-vision-holdings/934

    8/5/25 8:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Appoints Alex Wilkes as CEO

    Reade Fahs to Assume Executive Chairman Position Transition Effective August 1, 2025 National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced that its Board of Directors has appointed Alex Wilkes as the Company's next Chief Executive Officer, effective August 1, 2025, and he will join the Company's Board at that time. Mr. Wilkes succeeds Reade Fahs who will assume the role of Executive Chairman of the Board. Mr. Fahs will continue to work closely with Mr. Wilkes, ensuring a smooth transition. "National Vision has been on a journey of significant transformation for the past few years, and today I am pleased to announce the next chapter in that tran

    4/29/25 6:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Appoints Jim McGrann and Michael Nicholson to Board of Directors

    Enters into Cooperation Agreement with Engine Capital National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced the appointment of two new independent directors, Jim McGrann and Michael Nicholson to its Board of Directors (the "Board"), effective March 17, 2025. Mr. McGrann will serve on the Board's Compensation Committee and Mr. Nicholson will serve on the Board's Audit Committee and Nominating and Corporate Governance Committee. With the addition of Messrs. McGrann and Nicholson, the Board will expand from 9 to 11 members. The Board has also formed an Advisory Committee that will help oversee National Vision's ongoing transformation initiatives with

    3/17/25 4:05:00 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

    SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

    11/14/24 12:33:08 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

    SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

    11/12/24 4:45:48 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

    SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

    11/4/24 1:18:26 PM ET
    $EYE
    Ophthalmic Goods
    Health Care